INTRODUCTION
Ovarian cancer is the most lethal gynecological cancer due to late diagnosis and a high recurrence rate (70% of patients). Ovarian cancer metastasis is considered the major reason for poor clinical outcomes and cancer deaths. 1 Recently, the microenvironment has been recognized as a major factor influencing cancer growth and impacting the outcome of therapy. 2 The tumor microenvironment consists of cells derived from bone marrow, and these cells are essential for tumor recurrence and metastasis mediated by angiogenesis. 3 Within the microenvironment, we focused on the potential role of endothelial progenitor cells (EPCs). EPCs have an important role in tumor growth and metastasis. In addition, EPCs have been proposed as a potential target in cancer. [4] [5] [6] It is not fully understood how EPCs have disparate roles in ovarian cancer patients, and their role in the ovarian cancer microenvironment remains unknown. Here we demonstrate the effects of EPCs on cultured SKOV-3 and OVCAR-3 ovarian cancer cells.
Transforming growth factor-beta (TGF-β) is a pleiotropic cytokine that regulates cell proliferation, apoptosis, differentiation, migration and invasion. 7 TGF-β acts as a tumor suppressor by inhibiting cell proliferation, whereas as a tumor promoter, TGF-β induces an epithelial-mesenchymal transition (EMT), cell motility and invasion. 8 EMT has been recognized as a key process for embryonic development and metastasis. 9 Cells undergoing EMT downregulate the expression of the E-cadherin epithelial marker and increase the expression of N-cadherin, a mesenchymal marker. This process has been shown to proceed through a set of transcription factors including Snail and Twist. 10 In ovarian cancer, TGF-β-induced EMT is believed to have an important role in the regulation of cell invasion and metastasis. 11 Although the function of TGF-β in ovarian cancer has been extensively investigated, to our knowledge, no study has examined the effects of EPC on ovarian cancer cell behavior. Our present studies demonstrated that EPC-conditioned media (EPC-CM) contains factors that can induce SKOV-3 and OVCAR-3 cell migration, suggesting that EMT is involved in the progression of cancer. This study was undertaken to test the hypothesis that TGF-β secreted by EPC-CM induces ovarian cancer migration by activating EMT.
In the present study, we examined the possible role of EPC-CM in ovarian cancer cells. We showed that EPC-CM induces ovarian cancer cell migration by activating EMT. In EPC-CM, we found that the TGF-β level was significantly higher than in ovarian cancer cells alone. Next, we used an inhibitor of TGF-β in the EPC-CM group, and observed that TGF-β can have an important role in EPC-CM that induces ovarian cancer cell migration and EMT in ovarian cancer.
MATERIALS AND METHODS Patients
Peripheral blood samples of 20 patients with histologically proven ovarian cancer were collected before treatment.
Culture of EPC and preparation of EPC-CM
EPC culture and identification were described in our previous paper. 12 Total mononuclear cells were isolated from 20 ml samples of human peripheral blood from patients with ovarian cancer by density gradient centrifugation with Histopaque-1077 (density 1.077 g ml − 1 ; Sigma Aldrich, St Louis, MO, USA). mononuclear cells were plated in 1 ml endothelial growth medium (EGM-2; Lonza, Basel, Switzerland) on fibronectin-coated (Sigma Aldrich) 24-well plates. After 24 h, unattached cells were discarded and attached cells were cultured as before. Medium was replaced every 2 days thereafter, and each colony/cluster was followed up. After 7 days in culture, colony-forming cells were recognized as attached spindle-shaped cells. The adherent cells were incubated with DiI-acLDL (acLDL; Molecule Probes, Leiden, The Netherlands) and then fixed in 2% paraformaldehyde and counterstained with fluorescein isothiocyanate-labeled lectin from Ulex europaeus agglutinin (UEA-1; Sigma Aldrich). Then, the EPC-derived CM was harvested after 48 h. This collected soup was defined as EPC-CM (EPC-derived CM). The EPC-CM was prepared by filtration through a centrifugal filter unit (Millipore, Billerica, MA, USA) and used to seed ovarian cancer cells for experiments.
Ovarian cancer cells culture
The SKOV-3 and OVCAR-3 cell lines were established in our laboratory. SKOV-3 and OVCAR-3 cells were grown in Roswell Park Memorial Institute medium (Sigma, Oakville, ON, Canada) supplemented with 10% fetal calf serum (Hyclone Laboratories, Logan, UT, USA). Cultures were maintained at 37°C in a humidified 5% CO 2 atmosphere in air.
Antibodies and reagents
Polyclonal anti-β-actin antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The monoclonal anti-E-cadherin and anti-Ncadherin antibodies were obtained from BD Biosciences (Mississauga, ON, Canada). HRP-conjugated anti-mouse IgG was obtained from Bio-Rad Laboratories (Hercules, CA, USA). SB431542 was obtained from Sigma Aldrich.
Detection of cytokines by ELISA
SKOV-3 and OVCAR-3 cells were plated in six-well cell culture plates. After 24 h, the cells were treated with EPC-CM. After 24 h, the cells were collected. We measured levels of TGF-β in the EPC-CM group and the ovarian cancer cells alone group using ELISA kits according to the manufacturer's protocol (R&D Systems, Minneapolis, MN, USA).
Transwell migration assay
Migration was evaluated using a transwell migration assay. In brief, SKOV-3 and OVCAR-3 cells were, respectively, cultured in the presence of EPC-CM for 48 h, and then 5 × 10 4 SKOV-3 and OVCAR-3 cells were seeded into the upper chambers with an 8.0-mm pore size transwell (Costar, Cambridge, MA, USA). Roswell Park Memorial Institute media (600 μl) was placed in the lower chamber. After incubation for 6 h at 37°C in 5% CO 2 , the cells that had not migrated were removed from the upper surface of the filters using cotton swabs. Those that had migrated to the lower surface of the filters were fixed in methanol and stained with Giemsa's stain solution. Migration was determined by counting the cell number with a microscope. Five visual fields were randomly chosen for each assay. The average number of migrating cells in these five fields was taken as the cell migration number of the group.
Reverse transcription quantitative real-time PCR
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Reverse transcription was performed using 3 μg RNA, random primers and M-MLV reverse transcriptase (Promega, Madison, WI, USA). The primers used for SYBR Green reverse transcription quantitative real-time PCR (RT-qPCR) were as follows:
E-cadherin: 5′-ACA GCC CCG CCT TAT GAT T-3′ (sense) and 5′-TCG GAA CCG CTT CCT TCA-3′ (antisense); N-cadherin: 5′-GGA CAG TTC CTG AGG GAT CA-3′ (sense) and 5′-GGA TTG CCT TCC ATG TCT GT-3′ (antisense); Snail: 5′-CCC CAA TCG GAA GCC TAA CT-3′ (sense) and 5′-GCT GGA AGG TAA ACT CTG GAT TAG A-3′ (antisense); Twist: 5′-GGA GTC CGC AGT CTT ACG AG-3′ (sense) and 5′-TCTGGA GGA CCT GGT AGA GG-3′ (antisense); and GAPDH, 5′-TGGCACCCAGCACAATGAA-3′ and 5′-CTAAGTCATAGTCCGCCTAGAAGCA-3′. RT-qPCR was performed using the Applied Biosystems 7300 Real-Time PCR System (PerkinElmer, Waltham, MA, USA), which was equipped with a 96-well optical reaction plate. All RT-qPCR experiments were performed in triplicate, and the mean value was used for to determine the messenger RNA (mRNA) levels. Relative quantification of the mRNA levels was performed using the comparative Ct method with GAPDH as the reference gene and using the 2 −ΔΔCt formula.
Western blotting
Whole-cell extracts were run on a 7.5% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Total cell lysates were prepared using lysing buffer (Cell lysing buffer, Cell Signaling Technology, Danvers, MA, USA) containing a protease and phosphatase inhibitor cocktail. The protein concentration in the samples was determined using the BCA Protein Assay Kit (Pierce, Rockville, IL, USA). After blocking for 1 h with 5% skim milk/Tris-buffered saline-Tween, the membranes were blotted with the following primary antibodies overnight at 4°C: antibodies against E-cadherin and N-cadherin, and actin. After secondary staining with anti-rabbit or anti-mouse peroxidase-conjugated antibodies, blots were washed three times with Tris-buffered saline-Tween. Protein bands were visualized on Amersham Hyper-Max film using the ECL chemiluminescence system as recommended by the manufacturer (Amersham, Buckinghamshire, UK). 
Effects of the specific inhibitor SB431542
To determine whether the specific inhibitor SB431542 abolishes EPC-CMinduced cell migration and EMT, SKOV-3 and OVCAR-3 cells were treated with EPC-CM in combination with SB431542 (10 mM). The cells were seeded onto Matrigel-coated transwell inserts. After 48-h incubation, the non-invading cells were wiped from the upper side of the filter, and the invading cells were stained with Giemsa's stain. The levels of E-cadherin and N-cadherin mRNA in SKOV-3 and OVCAR-3 cells treated with SB431542 (10 mM) in the presence or absence of EPC-CM were analyzed by Twist mRNA levels were analyzed by RT-qPCR.
Statistical analysis
Statistical analyses were performed with software program SPSS 13.0 statistical software (SPSS, Chicago, IL, USA). The Mann-Whitney U-test and Student's t-test were used to compare variables between the two groups. Normalization criteria (control group cultures without EPC-CM considered as 100%) and data are shown as means ± s.e. Statistical significance was considered as Po0.05.
RESULTS

EPC-CM induces SKOV-3 and OVCAR-3 cell migration
To test the hypothesis that EPC-CM affects ovarian cancer cell migration, Matrigel-coated transwells were used. SKOV-3 and OVCAR-3 cells were incubated in the presence of EPC-CM for 48 h. As shown in Figure 1a and b, SKOV-3 and OVCAR-3 cells cultured in the presence of EPC-CM were highly migratory. Incubation of the cells in the presence of EPC-CM markedly increased ovarian cancer cell migration ability compared with ovarian cancer cells alone. Taken together, these observations indicate that EPC-CM can induce SKOV-3 and OVCAR-3 cell migration.
EPC-CM induces EMT in SKOV-3 and OVCAR-3 cells
The role of EPCs in regulating EMT in ovarian cancer remains relatively unexplored. Therefore, we treated the human cancer cell lines SKOV-3 and OVCAR-3 with EPC-CM to determine whether EPC-CM can initiate EMT, causing cells to lose cell-cell contacts and to change from a compact, epithelial morphology to a spindle-shaped fibroblastic morphology after 72 h (Figure 2a ).
We next sought to investigate the effects of EPC-CM on the epithelial marker E-cadherin and the mesenchymal marker N-cadherin by RT-qPCR and western blot. It has been suggested that a switch from E-cadherin to N-cadherin expression is a key feature during EMT. RT-qPCR analysis demonstrated that EPC-CM downregulated E-cadherin mRNA levels in SKOV-3 and OVCAR-3 cells, whereas the N-cadherin mRNA levels increased (Figure 2b) . These effects were confirmed at the protein level by western blot analysis. SKOV-3 and OVCAR-3 cells demonstrated E-cadherin downregulation and N-cadherin upregulation at the total protein level (Figure 2c) . These results indicate that EPC-CM enhances ovarian cancer cell migration and EMT through the molecules that they secrete. Levels of TGF-β secreted by EPC-CM The role of EPC-CM, particularly that of secretion of EPCs, in regulating EMTs in ovarian cancer remains relatively unexplored. We detected levels of TGF-β in the ovarian cancer cells in the presence of EPC-CM and in the ovarian cancer cells alone. Our results showed that the level of TGF-β with ovarian cancer cells in the presence of EPC-CM was markedly increased compared with ovarian cancer cells alone (Figure 3 ). We also detected levels of TGF-β in the EPC-CM. Our results showed that the levels of TGF-β is 324 pg ml − 1 , suggesting that EPC-CM can secrete TGF-β.
The specific inhibitor SB431542 abolished EPC-CM-induced SKOV-3, OVCAR-3 cell migration and EMT SB431542 is a potent and specific TGF-β inhibitor. Treatment with SB431542 significantly abolished the EPC-CM-induced change in the cell migration capability of SKOV-3 and OVCAR-3 cells (Figure 4a and b) . SB431542 treatment abolished the EPC-CM effects on E-cadherin and N-cadherin mRNA and protein levels (Figure 5a and b) . These findings suggest that TGF-β factor secreted by EPCs might have an important role in ovarian cancer cell EMT and migration.
EPC-CM induces EMT in SKOV-3 and OVCAR-3 cells by upregulating Snail and Twist
We next sought to better understand the mechanisms that mediate EPC-CM-induced EMT in SKOV-3 and OVCAR-3 cells. To investigate whether EPC-CM downregulates E-cadherin expression by modulating E-cadherin transcriptional regulation, we used RT-qPCR to examine the mRNA levels of the E-cadherin transcriptional repressors Snail and Twist. EPC-CM treatment significantly increased the Snail and Twist mRNA levels in SKOV-3 and OVCAR-3 cells (Figure 5c ). In addition, the EPC-CM-induced changes to the Snail and Twist mRNA levels were abolished by treatment with SB431542 ( Figure 5c ).
DISCUSSION
Ovarian cancer is a common cause of cancer death from a gynecologic tumor. Tumor metastasis commonly results in death in patients with ovarian cancer, and also is an important factor for clinical outcome. 13 Clearly, investigation of the mechanism of metastasis and potential associated factors would provide important evidence for improving treatment of ovarian cancer. In recent years, the interaction between tumor cells and microenvironment cells in the process of tumorigenesis has received much attention. 14 Among the microenvironment cells, we focused on EPCs that are known to be recruited to tumor sites and activated by cancer cells. EPCs are precursor cells of endothelial cells, which could potentially differentiate into endothelial cells and take part in tumor angiogenesis. It is known that angiogenesis have a very crucial role in tumorigenesis, progression and metastasis, so EPCs are closely associated with tumor metastasis. 15, 16 In the absence of evidence on how EPC could activate ovarian cancer and we choose to study the role of EPCs in ovarian cancer cells. We found that EPCs demonstrated ability to promote ovarian cancer cell migration. Our study demonstrates that there is an interaction between EPCs in patients with ovarian cancer, and that the ovarian cancer cells and EPC-CM can enhance the migration ability of the ovarian cancer cells by EMT.
Increasing evidence indicates that TGF-β functions as a tumor suppressor in early-stage tumors, whereas paradoxically acting as a tumor promoter in advanced cancers. 17, 18 The molecular nature of this switch is complicated and perhaps context dependent and remains largely unknown. Previous studies indicated that TGF-β induces serous borderline ovarian tumor cell invasion by activating EMT. 11 In humans, TGF-β overexpression has been detected in many cancer types and correlates with tumor metastasis, progression and prognosis. 19, 20 Many studies have indicated that TGF-β can function as a tumor suppressor and promoter depending on the context. Here we showed that the effect of the EPC could be mediated through the secretion of factors in the culture medium. Our study demonstrated that the EPC-CM contained TGF-β, by which EPCs affected the ovarian cancer cells.
Because SB431542 is a TGF-β inhibitor, it is not surprising that this compound completely blocked the effects of TGF-β on EMT and migration in SKOV-3 and OVCAR-3 cells. However, our results do not exclude the involvement of the non-canonical signaling pathways in TGF-β-induced EMT in SKOV-3 and OVCAR-3 cells. Thus, further investigation will be needed to address this issue. The transcription factors Snail and Twist have been well characterized for their important roles in the regulation of the EMT through decreased E-cadherin expression. In addition to their function in downregulating E-cadherin, Snail and Twist have been shown to upregulate N-cadherin. [21] [22] [23] Snail and Twist are involved in the EPC-CM-induced EMT in SKOV-3 and OVCAR-3 cells. In this study, EPC-CM alone induced Snail and Twist expression in SKOV-3 and OVCAR-3 cells, and these effects were abolished by the addition of the TGF-β inhibitor SB431542. Thus, additional studies will be required to examine the involvement of non-canonical signaling pathways in EPC-CM-induced Snail and Twist expression in SKOV-3 and OVCAR-3 cells. EPC-CM treatment induces SKOV-3 and OVCAR-3 cell migration by activating EMT. Elucidating the functions of EPC-CM in SKOV-3 and OVCAR-3 cells will increase our understanding of human ovarian cancer.
In conclusion, our study underlines the role of TGF-β in migration induced by EPC-CM secretions by activating EMT in ovarian cancer cells. The potential use of TGF-β inhibitor could overcome cancer cell migration and EMT. Molecules secreted by EPC-CM deserve a full characterization and will bring a better understanding of both microenvironment and cancer cell crosstalk and the mechanism leading to metastasis in the ovarian cancer model. Although further molecular mechanism and clinical studies are needed, application of EPCs shows great promise for targeting ovarian cancer metastasis.
